Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Richard Bluhm Clear advanced filters

  • Minority groups are often disproportionately exposed to air pollution, but what drives these disparities is difficult to analyse. Using the economic shutdown associated with the 2020 COVID-19 shelter-in-place orders, this study estimates pollution exposure disparities caused by the in-person economy in California.

    • Richard Bluhm
    • Pascal Polonik
    • Jennifer A. Burney
    Research
    Nature Sustainability
    Volume: 5, P: 509-517

  • Atrial fibrillation is a growing problem worldwide. Lee, Kruse and McCarthy review surgical options for the treatment and cure of atrial fibrillation. They discuss the classic maze procedure, new technologies that have allowed minimally invasive modifications of this procedure, and the future directions of surgical therapy for atrial fibrillation.

    • Richard Lee
    • Jane Kruse
    • Patrick M. McCarthy
    Reviews
    Nature Reviews Cardiology
    Volume: 6, P: 505-513

  • Fungi from the genus Fusarium are important pathogens of animals and crop plants. Some have a wide host range, whereas others are more specific in the organisms they infect. Here, clues are provided as to how differences in specificity come about. The genomes of two Fusarium fungi with differing host ranges have been sequenced, and compared with the genome of a third species. Experiments show that transferring two whole chromosomes turns a non-pathogenic Fusarium strain into a pathogenic one.

    • Li-Jun Ma
    • H. Charlotte van der Does
    • Martijn Rep
    ResearchOpen Access
    Nature
    Volume: 464, P: 367-373

  • In a randomized phase 2 clinical trial, the angiotensin receptor blocker valsartan improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, a condition for which there are no effective therapies for modifying disease progression.

    • Carolyn Y. Ho
    • Sharlene M. Day
    • Eugene Braunwald
    Research
    Nature Medicine
    Volume: 27, P: 1818-1824